Find therapies in clinical trials near you – page 9

Study on MK-2870, Pembrolizumab, and Chemotherapy for Patients with Advanced Gastroesophageal Cancer

Study on MK-2870, Pembrolizumab, and Chemotherapy for Patients with Advanced Gastroesophageal Cancer

Study on Reducing Chemotherapy Cycles with Pembrolizumab for Patients with PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer

Study on Reducing Chemotherapy Cycles with Pembrolizumab for Patients with PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer

Study on the Effectiveness of Pembrolizumab and Ipilimumab in Melanoma Patients with Brain Metastases Requiring Steroid Treatment

Study on the Effectiveness of Pembrolizumab and Ipilimumab in Melanoma Patients with Brain Metastases Requiring Steroid Treatment

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Study of Pembrolizumab for Patients with Mismatch Repair Deficient Uterine Cancer

Study of Pembrolizumab for Patients with Mismatch Repair Deficient Uterine Cancer

Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Study of Pembrolizumab with Etoposide and Cisplatin for First-Line Treatment in Patients with Small Cell Ovarian Cancer

Study of Pembrolizumab with Etoposide and Cisplatin for First-Line Treatment in Patients with Small Cell Ovarian Cancer

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Study on Heart Function Changes in Cancer Patients Treated with Nivolumab or Pembrolizumab

Study on Heart Function Changes in Cancer Patients Treated with Nivolumab or Pembrolizumab

Study of LY3537982 for Patients with Advanced Solid Tumors with KRAS G12C Mutation

Study on Pembrolizumab and Chemotherapy with Radiation for Advanced Non-Small Cell Lung Cancer Patients

Study on Pembrolizumab and Chemotherapy with Radiation for Advanced Non-Small Cell Lung Cancer Patients

Study of Pembrolizumab with Chemotherapy for Patients with HER2-Negative Inflammatory Breast Cancer

Study of Pembrolizumab with Chemotherapy for Patients with HER2-Negative Inflammatory Breast Cancer